Solution Based Therapeutics’ Post

Discover how Jess, HR Director at Lucy Therapeutics, leveraged Order.co's real-time spend data and custom reports to optimize cash flow. In this video, she shares insights on staying within budget, crucial for revenue-generating phases. With enhanced tools and visibility, Jess ensures seamless budget management for her team. Watch now to learn more: https://hubs.la/Q02zVNxY0 #budgetmanagement #spenddata #cashflowmanagement

💡 Better Therapeutics to Seek Strategic Alternatives, Delisting from Nasdaq Better Therapeutics announced that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on March 13, 2024. Further, as previously disclosed, the Company’s securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq’s continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be delisted in the near term. Melis Ince, Head Analyst, comments 👇 Better Therapeutics is one of the digital therapeutics solution providers which went public via SPAC deal in 2021. Since the launch of AspyreRx #prescription #digitaltherapeutics solution for #Type2diabetes in October 2023, Better Therapeutics has been putting efforts in the commercialization of the product in the US market. They announced several partnerships with pharmacy benefits providers and digital health platforms like Glooko. The company also recently added another FDA Breakthrough Device Designation for its #DTx product targeting advanced #liver disease. However, despite several attempts to strengthen its financial position, and also laying off its 35% of workforce a year ago, it was not enough to continue for the company. A business model based solely on #reimbursements and prescriptions for DTx solutions in the US market seems to be one of the most challenging routes to follow. ✔ There is more news, comments, analyses & #competitor and #market trends on Allis.Health, the global analyst platform for the #digitalhealth industry. https://allis.health/ Want to explore further? 💡 Contact us at hello@allis.health to arrange a demo session and get started with a free trial. #digitalhealth #globalhealth #digitaldiabetes #analystview

🚀 Big moves in #Biotech! Johnson & Johnson has just levelled up their game with a bold $1.25B acquisition. 🧬 Yellow Jersey Therapeutics is now part of the J&J family, bringing a promising eczema drug, NM26, to the forefront of skin disease innovation. Gear up for Phase 2 trials that could redefine comfort for those battling atopic dermatitis.✨ While competitors are watching closely, J&J's playbook is clear: Deliver "distinctive benefits" with a therapy tackling both inflammation and itching. It's a strategic play in a market hungry for more effective treatments.🎯 As a seasoned headhunter in HealthTech, I recognize the profound impact such advancements have on the industry. Bringing in executives who can steer these innovations to market is what I do. 🌐 If you're a decision-maker eager to shape the future of MedTech or an executive ready to take on the challenge, let's revolutionize healthcare together.🤝 #InnovationInHealth #EczemaTreatment #JNJAcquisition

💡 2024 forecast: Digital therapeutics makers will have to get creative to conquer reimbursement issues The article discusses the challenges faced by #DTx companies, despite promising study results and FDA approvals. Companies like Better Therapeutics, Akili, and Pear Therapeutics have struggled financially, leading to layoffs, pipeline cuts, and strategy shifts.  - The lack of #payer support for DTx has been a significant roadblock, as insurers have been reluctant to cover these technologies.  - #Reimbursement issues have been cited as a core challenge to profitability for digital therapeutics makers. The article suggests two potential opportunities for digital therapeutics: fitting into larger digital-enabled ecosystems and becoming part of the broader landscape of #remotecare. Susanne Gruber, #DTx Channel #Ambassador, comments 👇 📈 Finding the most promising business model is still a critical exercise for start-ups. The assumption, that a DTx can follow the reimbursement path like a drug has proven to be challenging for now. Despite all the innovation in healthcare do we not see a fast adoption of the healthcare system and processes as such. 🧩 Another piece of the puzzle that leads to financial problems of digital health companies is the fast, and sometimes unstructured growth of organisations. The smart start-ups and investors believe in careful organisational growth that follows the financial growth. ❗ Whenever you look for a partner or a company to invest in, make sure your due diligence includes organisational development. ✔ There is more news, comments, analyses & #competitor and #market trends on Allis.Health, the global analyst platform for the #digitalhealth industry. 🌐https://allis.health/ Want to explore further? 💡 Contact us at hello@allis.health to arrange a demo session and get started with a free trial. #digitalhealth #DTx #digitaltherapeutics #marketinsights #healthcareperspective #expertviews

Allogene Therapeutics (NASDAQ:ALLO) shares tumbled at the open Friday after the company revealed plans to cut 22% of its workforce, part of a strategic shift in pipeline prioritization and clinical development strategy. The company anticipates completing the workforce reduction by the end of January 2024, with estimated charges of approximately $5 million to $5.5 million for severance payments and employee benefits, primarily in the first quarter of 2024. In addition to the layoffs, Allogene announced the discontinuation of two trials, ALPHA2 and EXPAND. Allogene also disclosed plans for autoimmune studies in 2025, leveraging Dagger technology to potentially eliminate the need for lymphodepletion, a development that could be game-changing in the CAR-T space. More at #Proactive #ProactiveInvestors #NASDAQ #ALLO http://ow.ly/Emw71057Xll

🎥 Exploring the Dynamics of Successful Partnerships and Sustainable Revenue Models in Digital Therapeutics: Join us for Part 2 of Allis.Health's #ExpertTalks Series featuring Alex Therapeutics! Engage in an insightful conversation between Paul Kirchmeier, COO of Alex Therapeutics, and Susanne Gruber, Strategic Healthcare Advisor at Ignited Vision by Susanne Gruber and Allis.Health's #DTx channel #Ambassador. 🤝 Together they delve into the dynamics and drivers behind successful #partnerships with global pharma companies like Pfizer and Vicore Pharma AB. Additionally, examine the viability of digital therapeutics #prescriptions and their associated #reimbursement pathways as revenue sources and sustainable #business models for #DTx companies. If you missed Part 1 of the interview, you can catch up here: https://bit.ly/3V37cyL And gain insights into:  ✔️ Alex Therapeutics' Origins ✔️ Company's distinctive service offerings and focus on targeted disease areas. ✔️ Strategies employed for success in navigating #multidimensional #Business & #Markets ✔️ Techniques utilized by Alex Therapeutics to drive user #motivation and ensure program #adherence. If you're eager to watch the complete Expert Talk video featuring Paul Kirchmeier, subscribe to Allis.Health. To enhance your experience further, request a demo by emailing us at hello@allis.health #globalhealth #healthcare #healthcareleaders #DTx #marketstrategy #successstory #globalhealth

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

Allyson Pelletier's words speak volumes about our dedication at Solution Based Therapeutics! We take pride in going the extra mile to simplify your job search journey. From scheduling and negotiation to finding the perfect fit, we're committed to your success every step of the way. #customerreview #solutionbasedtherapeutics #healthcarerecruitment #staffing #healthcareprofessionals #mentalhealth #healthcareindustry #recruitmentagency

📉 Tough Times for Biotech! 🧪💼 The biotech industry faced its toughest year in 2023, with a record high of 18 companies filing for bankruptcy since 2010. Sorrento Therapeutics, Infinity Pharmaceuticals, and OncoSec Medical were among those hit hard. Now, as we step into 2024, Humanigen and Athersys have already joined the list of casualties. Despite past reorganisations, financial struggles persist for many biotech firms. The healthcare sector, overall, faces challenges, ranking third in bankruptcy filings by sector in early 2024. High interest rates and a challenging labor market continue to pose obstacles. Read more about the industry's challenges and strategies in the full article in the comments. Feel free to engage with this post by liking, sharing, commenting, or reaching out if you're interested in learning more, or if you were affected by layoffs and need support 💪 #biotechnology #aritificialintelligence #inthistogether

A Personal Milestone: trifermed's Leap into Boston Today marks a significant chapter in my journey with trifermed. As the founder, I'm thrilled to announce our expansion into Boston - a dream that has been in the making since 2016 and intensely pursued over the past two years. This step isn't just about geographical growth; it's the culmination of a dedicated, strategic effort. In 2016, we envisioned a future where trifermed would play a pivotal role in a leading hub of health innovation like Boston. To realize this vision, I transitioned my role as CEO to the capable hands of Ricardo Acin Aznar and Daniel Gonzalez. This move allowed me to delve deeper into the biopharmaceutical landscape, taking on C-Level roles to gain firsthand insights into the challenges and needs of the North American market. These experiences weren't just enlightening; they were transformational. They equipped me with a profound understanding of what it takes to succeed in this dynamic environment. Every step, every decision, has been geared towards one goal: to position trifermed at the forefront of health innovation, bridging groundbreaking ideas with market success. As we embark on this new journey in Boston, I am filled with excitement and commitment. This is more than an expansion; it's a testament to our relentless dedication and a promise of the incredible value we aim to bring to the global healthcare industry. I am deeply grateful for the trust, support, and hard work of everyone at trifermed that made this possible. Together, we are set to make a significant impact, and I can't wait to see the wonders we will achieve. Let's shape the future of healthcare, together! #trifermed #Boston #HealthcareInnovation #Leadership #CorporateStrategy #Biopharmaceuticals